AGMB Stock Chart & Stats
$11.33
--
Market closed
$11.33
--
Day’s Range― - ―
52-Week Range$8.75 - $17.82
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$565.35M
Enterprise Value$432.05M
Total Cash (Recent Filing)$116.51M
Total Debt (Recent Filing)$1.25M
Price to Earnings (P/E)―
Beta1.24
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding49,247,974
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio4.26
Price to Book (P/B)4.64
Price to Sales (P/S)0.00
P/FCF Ratio-11.74
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-24.52
Forecast
1Y Price Target
$26.52Price Target Upside134.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AgomAb Therapeutics NV ADR News
AGMB FAQ
What was AgomAb Therapeutics NV ADR’s price range in the past 12 months?
AgomAb Therapeutics NV ADR lowest stock price was $8.75 and its highest was $17.82 in the past 12 months.
What is AgomAb Therapeutics NV ADR’s market cap?
AgomAb Therapeutics NV ADR’s market cap is $565.35M.
When is AgomAb Therapeutics NV ADR’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were AgomAb Therapeutics NV ADR’s earnings last quarter?
Currently, no data Available
Is AgomAb Therapeutics NV ADR overvalued?
According to Wall Street analysts AgomAb Therapeutics NV ADR’s price is currently Undervalued.
Does AgomAb Therapeutics NV ADR pay dividends?
AgomAb Therapeutics NV ADR does not currently pay dividends.
What is AgomAb Therapeutics NV ADR’s EPS estimate?
AgomAb Therapeutics NV ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AgomAb Therapeutics NV ADR have?
AgomAb Therapeutics NV ADR has 49,247,974 shares outstanding.
What happened to AgomAb Therapeutics NV ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of AgomAb Therapeutics NV ADR?
Currently, no hedge funds are holding shares in AGMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AgomAb Therapeutics NV ADR Stock Smart Score
Company Description
AgomAb Therapeutics NV ADR
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
AGMB Stock 12 Month Forecast
Average Price Target
$26.52
▲(134.04% Upside)
Ownership Overview
―
Insiders
3.24% Mutual Funds
3.12% Other Institutional Investors
93.52% Public Companies and
Individual Investors

